Richmond Club IndexTSX Venture
S&P 500
Theoretical Richmond
Fund 1% MER
Berkshire Hathaway
19.74%
-7.31%
5.85%
13.96%
9.40%
Celebrating its 19th year of helping its members
outperform the market

MEI Pharma Inc. – Developing therapies for cancer

Company: MEI Pharma Inc.
Symbol: MEIP:US
Length: 00:25:55
Presenter: Dr. Dan Gold, President & CEO
Occasion: Richmond Club Lunch, Toronto

MEI Pharma is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer.

Additional Information

MEI Pharma is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our portfolio of drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Our clinical development pipeline also includes ME-401, a highly selective, oral PI3K delta inhibitor, voruciclib, an oral, selective CDK inhibitor, and ME-344, a novel mitochondrial inhibitor.

Head Office:

MEI Pharma, Inc.
3611 Valley Centre Drive, Suite 500
San Diego, CA 92130

(858) 369-7100

W: www.meipharma.com

Be the first to comment

Leave a Reply

Your email address will not be published.


*